Details of the Drug

General Information of Drug (ID: DMV401D)

Drug Name

Debio-0824

Synonyms

Shk-192; ShK analogs (Subcutaneous formulation, autoimmune disease), Kineta; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease); Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (Subcutaneous formulation, autoimmune disease), Airmid; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (injectable peptide, autoimmune disease), Davis; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease), Kineta One

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 1b/2a	[1]
Psoriatic arthritis	FA21	Phase 1	[2]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D01XEO

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated potassium channel Kv1.3 (KCNA3)	TTY3UE6	KCNA3_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2	ClinicalTrials.gov (NCT02446340) Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers. U.S. National Institutes of Health.
3	Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653.